RECURSION PHARMACEUTICALS, INC. Financials Recursion Pharmaceuticals, Inc.
Equities
RXRX
US75629V1044
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.12 USD | +3.57% |
|
+10.48% | -17.65% |
| Apr. 18 | Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing | MT |
| Apr. 16 | Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,895 | 1,461 | 2,136 | 1,932 | - | - |
| Enterprise Value (EV) 1 | 2,379 | 918.1 | 1,745 | 1,610 | 1,654 | 1,660 |
| P/E ratio | -11.5 x | -5.67 x | -6.24 x | -4.78 x | -4.33 x | -6.58 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 284 x | 36.7 x | 47.9 x | 35.8 x | 31.9 x | 12.8 x |
| EV / Revenue | 234 x | 23 x | 39.2 x | 29.9 x | 27.3 x | 11 x |
| EV / EBITDA | -13.6 x | -3.92 x | -5.36 x | -3.94 x | -3.27 x | -3.33 x |
| EV / FCF | -12 x | -7.61 x | -5.82 x | -4.27 x | -3.99 x | -6.13 x |
| FCF Yield | -8.34% | -13.1% | -17.2% | -23.4% | -25% | -16.3% |
| Price to Book | 5.37 x | 2.79 x | 4.97 x | 5.79 x | 8.98 x | 12.7 x |
| Nbr of stocks (in thousands) | 168,993 | 189,556 | 216,623 | 237,983 | - | - |
| Reference price 2 | 17.13 | 7.710 | 9.860 | 8.120 | 8.120 | 8.120 |
| Announcement Date | 3/23/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.962 | 10.18 | 39.84 | 44.58 | 53.92 | 60.67 | 151.4 |
| EBITDA 1 | - | -174.4 | -234 | -325.7 | -408.5 | -506.1 | -499 |
| EBIT 1 | - | -182.8 | -245.7 | -350.1 | -425.2 | -506.3 | -467.2 |
| Operating Margin | - | -1,795.79% | -616.74% | -785.33% | -788.59% | -834.61% | -308.5% |
| Earnings before Tax (EBT) 1 | - | -186.5 | -239.5 | -332.1 | -438 | -533 | -398 |
| Net income 1 | -87.01 | -186.5 | -239.5 | -328.1 | -410.5 | -481.2 | -398 |
| Net margin | -2,196.01% | -1,832.18% | -601.05% | -735.99% | -761.41% | -793.21% | -262.8% |
| EPS 2 | -5.990 | -1.490 | -1.360 | -1.580 | -1.699 | -1.877 | -1.234 |
| Free Cash Flow 1 | - | -198.4 | -120.6 | -299.7 | -377 | -414 | -271 |
| FCF margin | - | -1,949.42% | -302.65% | -672.43% | -699.2% | -682.41% | -178.95% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/3/21 | 3/23/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.534 | 2.533 | 5.333 | 7.674 | 13.16 | 13.68 | 12.13 | 11.02 | 10.53 | 10.89 | 13.07 | 13.58 | 14.17 | 14.35 | 13.5 |
| EBITDA 1 | - | - | - | - | -59.58 | - | -66.14 | -76.17 | - | -91.38 | -91.3 | -91.3 | -89.8 | -184.8 | -201.4 |
| EBIT 1 | -46.4 | -64.96 | -55.98 | -66.19 | -62.57 | -60.98 | -69.86 | -81.72 | -99.55 | -98.93 | -100.1 | -101.6 | -103 | -130.7 | -154.8 |
| Operating Margin | -1,831.18% | -2,564.55% | -1,049.71% | -862.54% | -475.48% | -445.91% | -575.78% | -741.72% | -945.12% | -908.36% | -765.83% | -747.86% | -726.77% | -910.8% | -1,146.3% |
| Earnings before Tax (EBT) 1 | -47.43 | -64.93 | - | -65.56 | -60.44 | -57.49 | -65.33 | -76.73 | -93.02 | -94.62 | -106 | -106 | -108 | -117 | - |
| Net income 1 | -47.43 | -64.93 | -55.98 | -65.56 | -60.44 | -57.49 | -65.33 | -76.73 | -93.02 | -93 | -98.92 | -99.42 | -99.68 | -126 | -154.8 |
| Net margin | -1,871.67% | -2,563.48% | -1,049.67% | -854.31% | -459.31% | -420.39% | -538.38% | -696.43% | -883.1% | -853.88% | -757.08% | -731.96% | -703.59% | -878.4% | -1,146.3% |
| EPS 2 | -0.2800 | -0.3800 | -0.3300 | -0.3800 | -0.3500 | -0.3000 | -0.3400 | -0.3800 | -0.4300 | -0.4200 | -0.4160 | -0.4133 | -0.4085 | -0.4836 | -0.6750 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/23/22 | 5/10/22 | 8/9/22 | 11/8/22 | 2/27/23 | 5/8/23 | 8/8/23 | 11/9/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 516 | 543 | 390 | 322 | 279 | 272 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -198 | -121 | -300 | -377 | -414 | -271 |
| ROE (net income / shareholders' equity) | - | -111% | -46.6% | -69.1% | -98.9% | -157% | -205% |
| ROA (Net income/ Total Assets) | - | -41% | -36.5% | -48.4% | -75.2% | -114% | -98.3% |
| Assets 1 | - | 454.5 | 655.8 | 677.5 | 546.2 | 421.4 | 404.7 |
| Book Value Per Share 2 | - | 3.190 | 2.770 | 1.980 | 1.400 | 0.9000 | 0.6400 |
| Cash Flow per Share 2 | - | -1.270 | -0.4800 | -1.380 | -0.9900 | -0.5800 | - |
| Capex 1 | - | 39.8 | 37.1 | 12 | 13 | 14 | 16 |
| Capex / Sales | - | 391.02% | 93.01% | 26.82% | 24.11% | 23.08% | 10.57% |
| Announcement Date | 3/3/21 | 3/23/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.12
USD
Average target price
13
USD
Spread / Average Target
+60.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.65% | 1.93B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RXRX Stock
- Financials Recursion Pharmaceuticals, Inc.
